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Background/aim: This study aimed to analyze the serum melatonin levels and changes in sleep patterns in pediatric patients with
coronavirus disease 2019 (COVID-19).
Materials and methods: This study was designed as a descriptive, cross-sectional study. Serum melatonin levels and sleep parameters
of children with the diagnosis of COVID-19 who had mild and moderate disease (i.e., COVID-19 group) were compared with those of
children admitted with non-COVID-19 nonspecific upper respiratory tract infection (i.e., control group). The sleep disturbance scale
for children (SDSC) questionnaire was applied to the participants› primary caregivers to analyze their sleep patterns at present and six
months before symptom onset and to investigate the impact of COVID-19 on sleep patterns.
Results: The entire study cohort consisted of 106 patients. The COVID-19 group included 80 patients, while the control group
consisted of 26 patients. The mean serum melatonin levels were 136.72 pg/mL and 172.63 pg/mL in the COVID-19 and control groups,
respectively (p = 0.16). There was no significant difference between the groups in terms of 6 subcategories of the SDSC questionnaire
regarding the present time and 6 months before symptom onset. The total SDSC scores were also similar in two different evaluation time
points described above (p = 0.99).
Conclusions: We conclude that COVID-19 did not impact the sleep parameters of children. Serum melatonin levels of all patients
were higher than the reference range; however, they were higher in the non-COVID-19 patient group than the COVID-19 group. Since
serum melatonin levels were higher than the reference values in children with COVID-19, and this disease is significantly less morbid
in children, melatonin may have protective effects against COVID-19.
Key words: Melatonin, sleep, pediatric, COVID-19, children

1. Introduction
Melatonin is a hormone secreted by the pineal gland,
and it is the primary regulator of sleep1. Although it is
known that melatonin has antiinflammatory, antioxidant,
and immunomodulatory functions during infection with
bacteria and viruses, its specific role in the novel coronavirus
disease 2019 (COVID-19) has not been widely investigated
[1]. To date, data obtained regarding COVID-19 infection
showed significantly lower morbidity and mortality rates
in the young patient population and children [1–3]. This
finding implies that patient age may have a critical role in
this disease’s pathogenesis. Since the serum concentration
of melatonin is inversely correlated with age, it would not be
unreasonable to investigate the potential role of melatonin
in the pathogenesis and progress of COVID-19 [1–2,4].

Photosensitive retinal-containing receptors mediate
the release of melatonin from the pineal gland [4]. Thus,
its secretion is inhibited during daylight. It is known that
COVID-19 is a zoonotic disease, and bats are the natural
carriers of coronavirus [4]. Bats are nocturnal hunters;
they avoid daylight and hide in dark caves during the
daytime. As a result, they continuously have high levels of
melatonin compared to the human. Coronavirus infection
is not fatal in bats with minimal or no symptoms. Despite
these facts, the alleviating role of melatonin hormone or
relatively high serum melatonin concentrations in the
young patient population and children with COVID-19
has not been investigated.
This study aimed to analyze the protective role of
melatonin in children with COVID-19 infection. Also,
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we aimed to investigate these children’s sleep patterns to
interrogate the relationships between melatonin levels and
sleep patterns and the impact of COVID-19 on the sleep
patterns of these patients.
2. Materials and methods
This study was approved by the Ethical Review Committee
of Ankara City Hospital (06.06.2020/E1-20-564). Pediatric
patients admitted to Ankara City Hospital, Pediatric Health
Center after confirmation of COVID-19 infection between
June 2020 and August 2020 by at least two positive PCR test
results, were included in this prospective study. Children
hospitalized at the same center with the clinical suspicion
of COVID-19 but had at least two negative PCR test results
constituted the control group. These control group patients
presented with high fever and other nonspecific upper
respiratory tract infection symptoms without an apparent
history of contact with known COVID-19 cases. The age
range of the target population was 6–16 years since the
sleep disturbance scale for children (SDSC) questionnaire
assesses children and adolescents in this age group [5,6].
Patients with a history of previous COVID-19 infection,
history of melatonin treatment in the previous 4 weeks,
sleep apnea syndrome, chronic neuromuscular disease,
and those whose legal guardians did not give consent were
excluded. The study participant flowchart is shown in
Figure 1. The COVID-19-positive patients were classified
according to disease severity based on clinical and
laboratory data [7]. Patients with no clinical symptoms or

findings and normal chest imaging results were classified
as asymptomatic, while those who had a high fever (i.e.,
a temperature higher than 37.8 °C), myalgia, throat pain,
coughing, or nasal discharge with normal findings of
lung auscultation were classified as a mild disease. On the
other hand, patients who had a high fever, coughing, or
wheezing accompanied by pneumonia or those who had
COVID-19-associated changes in their computerized
chest tomography without clinical findings were classified
as a moderate disease. Patients who had dyspnea and low
oxygen saturation (i.e., < 92%) were classified as severe,
and those who had rapidly progressing acute respiratory
distress syndrome or respiratory failure with multiple
organ dysfunction were classified as critical.
Waldhauser et al. analyzed the alterations in serum
melatonin levels with growing and aging [2]. The reported
values in this study were used as references of serum
melatonin values. These authors reported that the mean
serum melatonin levels were 160 pg/mL for the 6–7 age
group, 110 pg/mL for the 7–12 age group, 85 pg/mL for the
12–15 age group, and 55 pg/mL for patients older than 15.
2.1. Sample collection
Serum samples were collected from all patients on the day
of admission and within three days of their first symptoms
for analyzing the melatonin levels. They were collected
between 06:00 and 07:00 am in the dim light of less than 30
lux (i.e., standard hospital lighting) from the patients after
overnight fasting. Postural conditions and environmental
lighting were the same for all patients during venipuncture.

Figure 1. Flowchart of the study.
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First, 2 mL of blood was drawn from the antecubital vein
and subsequently centrifuged. The serum was kept at –20
°C. All study participants went to bed between 21:30 and
22:30 and woke up between 07:00 and 08:00 am. Serum
melatonin levels were analyzed using the ELISA method
(Human Melatonin ELISA kit, Catalogue Number:
E1013Hu, Bioassay Technology Laboratory, Shanghai,
China).
2.2. Sleep disturbance scale for children
The SDSC questionnaire was applied to the primary
caregivers by the same researcher (P.G.) on the phone.
The primary caregiver was requested first to answer the
questions considering the last week, which covered disease
onset (i.e., present time) and second by considering the six
months before infection (i.e., 6 months before symptom
onset). The primary reason for the evaluation of sleep at
two different time frames was analyzing the impact of
COVID-19 infection on the patients’ sleep characteristics
and comparison of the patients and controls in this
regard. This questionnaire containing 27 Likert-type
questions was designed to evaluate sleep disturbances in
children and adolescents and was validated for the Turkish
language [5,6]. It evaluates subsets of sleep disturbances,
namely, disorders of initiating and maintaining sleep,
sleep breathing disorders, disorders of arousal, sleep-wake
transition disorders, disorders of excessive somnolence,
and sleep hyperhidrosis) in children and adolescents. The
cut-off point is 39 on this scale; points higher than this are
associated with sleep disturbances [5]. A reliability test has
been performed in order to test the data set obtained from
the questionnaire forms. Alpha coefficient (Cronbach’s
alpha) has been used for reliability analysis. Sleep disorders
in children have been measured using a questionnaire
consisting of 24 questions and the reliability of the sleep
disorder scale was found to be 0.840 for the last 6 months
and 0.825 for the last week.
2.3. Statistical analysis
Data analyses were performed using IBM SPSS Statistics
v. 23.0 (Armonk, NY, USA). Whether the distribution of
continuous variables was normal or not was determined by
the Kolmogorov–Smirnov test. The Levene test was used
for the evaluation of the homogeneity of the variances.
Unless specified otherwise, continuous variables were
presented as means± standard deviations (SD) for normally
distributed data, and medians and ranges (i.e., minimum
and maximum values) for data with skewed distribution.
Categorical variables were given as the numbers (n) or
percentages (%). The student’s t test was used to compare
continuous normally distributed variables between two
independent groups, while the Mann–Whitney U test was
implemented for comparing the nonnormally distributed
data. Categorical variables were compared using the
Pearson chi-square test or Fisher exact test. Correlations

1642

between variables were evaluated using the Pearson or
Spearman correlation analysis. A p value of less than 0.05
was considered significant.
3. Results
The target population of this study included 118 patients.
Five patients who refused to give blood samples, 5 patients
whose primary caregivers could not provide the authors
with reliable data, and 2 patients with inconclusive
laboratory data were excluded. Thus, the entire study
cohort consisted of 116 patients. Among these patients, 58
were COVID-19 patients, while 26 patients were assigned
to the control group for measuring serum melatonin
levels, and 65 were COVID-19 patients, while 20 patients
were assigned to the control group for applying SDSC
(Figure 1). All COVID-19 patients had either mild (85%)
or moderate disease (15%) based on the classification.
Demographic data of the patients and serum melatonin
levels are shown in Table 1. Comparative analysis revealed
that serum melatonin levels were relatively lower in
the COVID-19 patient group than the control group.
However, the difference was not statistically significant
(Table 1, Figure 2).
The differences in serum melatonin levels were
evaluated by grouping the participants based on their age
and corresponding reference levels, as shown in Table
2. There were 5 patients in the 6–7-year-old age group.
However, since there were no control group patients in this
age group, they were not included in Table 2. The serum
melatonin levels were higher than the age-referenced
values in both patient groups of our study (Table 3) [2].
Comparison of the serum melatonin levels based on patient
age elucidated that the COVID-19 patients had lower
serum melatonin levels than the patients in the control
group in all age subgroups. Although serum melatonin
levels of our COVID-19 patients were lower than control
group patients in all age groups, a statistically significant
difference was detected only in the 7–11 age group (p =
0.03). All study participants, except for the COVID-19
patients in the 7–12 age group, had significantly higher
serum melatonin levels than the reference values (Table 3).
Comparison of sleep parameters regarding 6 months
before symptom onset and present time between
COVID-19 patients and control group patients are
displayed in the Appendix. There was no significant
difference regarding the six subsets of sleep disturbances
evaluated by SDSC performed based on 6 months before
symptom onset and current data. The changes in the SDSC
subset scores and total scores are displayed in Table 4.
The comparison of both total SDSC scores and SDSC
subcategory scores of two time points (i.e., 6 months before
symptom onset vs. present time) revealed no statistically
significant difference between the two groups (p = 0.99).
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Table 1. Age, sex, and serum melatonin levels of the participants.
COVID-19-positive
(n: 58)

COVID-19-negative
(n: 26)

Male

34 (58.6%)

20 (76.9%)

Female

24 (41.4%)

6 (23.1%)

Age (mo, mean ± SD)

156.42 ± 42.33

155.12 ± 38.30

0.13

Serum melatonin
(pg/mL, median, min-max)

136.72
(48.09–1217.13)

172.63
(59.16–1171.09)

0.16

Sex (n,%)

Figure 2. Serum melatonin levels based on COVID-19 positive
and control group.

A review of the SDSC scores of the COVID-19 patients
showed that 4 (6.2%) patients had scores higher than 39
(i.e., the cut-off value) in the ‘present time’ evaluation,
while 5 (7.7%) patients had scores higher than 39 in the
evaluation regarding 6 months before symptom onset.
One particular control group patient had SDSC scores
higher than 39 in both evaluations regarding the present
time and six months before symptom onset.
4. Discussion
To the best of our knowledge, this study was the first to
investigate the serum melatonin levels and sleep patterns
in children with COVID-19. The role of melatonin in
COVID-19 is still unclear, as data concerning this disease’s
pathophysiology is still accumulating [8]. In the adult and
elderly population, melatonin is thought to have beneficial
effects providing better clinical outcomes for COVID-19
patients admitted to critical care units [1]. Melatonin exerts
these positive effects by reducing vessel permeability,
decreasing anxiety and sedation need, and improving
sleep quality. Therefore, some researchers advocated its

P-value
0.11

use as adjuvant therapy. In our study, serum melatonin
levels were lower in children and adolescents with mild or
moderate COVID-19 than the control group patients with
nonspecific upper respiratory tract infections. However,
the difference was not statistically significant. Also, serum
melatonin levels of the children and adolescents in both
COVID-19 and control groups were significantly higher
than the reference values adjusted for age [2]. This finding
leads to the hypothesis that serum melatonin levels increase
during the acute phase of all viral infections, including
the new type of coronavirus infection. The common
denominator of studies investigating the relationship of
melatonin with viral, bacterial, and parasitic infections is
the expectation of using melatonin to treat these infections
[9–11] However, none of these studies were conducted
with pediatric patients.
Serum melatonin concentrations start to decline with age
after the neonatal period [2]. Contrary to this information
and the reference values obtained from healthy children,
average melatonin levels of 12–15 years old children were
higher than that of patients who were 15 years old and
older [2]. Although conflicting data exist, a manuscript
published in 1992 reports a minor increase in melatonin
levels during the puberty [12]. We compared the melatonin
levels between COVID-19 positive patients and COVID-19
negative patients with an infection and did not observe
serum melatonin levels showing a positive correlation with
age in either group, contrary to data from healthy children.
This observation leads to the question of whether there is an
age-related difference between healthy and infected children
concerning serum melatonin levels however, there is no
study investigating this question in the literature. We were
not able to test this hypothesis since healthy controls were
not included in our study. Crowley et al. have investigated the
relationship between light exposure and melatonin secretion
from the pineal gland and have compared pre-mid and late
pubertal melatonin levels. The authors stated that pre- to
mid-pubertal group showed significantly greater melatonin
suppression on light exposure but no significant differences
were seen between pre-, mid, and late pubertal groups in
morning melatonin suppression [13]. This study shows that
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Table 2. Comparison of the serum melatonin levels based on age.
Serum melatonin levels (n: 84) (median, min-max)
Age groups

P-value

COVID-19-positive
(n: 58)

COVID-19-negative
(n: 26)

7–12 years (n: 30)

119.33 (65.30–370.31)

182.68 (85.14–1171.09)

0.03

12–15 years (n: 25)

116.86 (69.64–849.81)

137.39 (59.16–213.75)

0.99

15 years or older (n: 24)

139.21 (48.09–1217.13)

172.63 (133.41–227.83)

0.79

Table 3. Comparison of melatonin levels between the COVID-positive patients and the control group based on age (age-based reference
values have been added from reference 2).

Age

Reference values
(pg/mL)

7–12 years
(n: 30)

Serum melatonin levels (n: 84) (median, min-max)
COVID-19-positive
(n: 58)

COVID-19-negative
(n: 26)

P-value1,2*

110

(n: 14) 119.33
(65.30–370.31)

(n: 16) 182.68
(85.14–1171.09)

0.021
0.182

12–15 years
(n: 25)

85

(n: 19) 116.86
(69.64–849.81)

(n: 6) 137.39
(59.16–213.75)

0.021
0.052

15 years or older (n: 24)

55

(n: 20) 139.21
(48.09–1217.13)

(n: 4) 172.63
(133.41–227.83)

0.0021
0.0082

*P value1 indicates to comparison of reference value and non-COVID-19 control group, P value2 indicates comparison of COVID-19
positive group and reference values.
Table 4. Summary of the temporal changes in the SDSC subcategories of COVID-19 positive group.
COVID-19 positive
Total score
Initiating and maintaining sleep
Sleep breathing disorders
Disorders of arousal
Sleep-wake transition disorders
Excessive somnolence
Sleep hyperhidrosis

1644

6 months prior to onset

Onset of infection

Change

r

–0.031

–0.013

–0.088

P

0.834

0.927

0.550

r

–0.038

–0.045

–0.050

P

0.793

0.759

0.732

r

0.203

0.063

–0.072

P

0.162

0.666

0.623

r

0.038

0.037

–0.082

P

0.795

0.800

0.577

r

0.086

0.152

0.204

P

0.556

0.297

0.159

r

–0.047

–0.065

–0.145

P

0.746

0.658

0.319

r

–0.017

–0.064

–0.115

P

0.908

0.663

0.432
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phases of puberty affect melatonin secretion patterns. This
points out to the notion that melatonin secretion as a proinflammatory or antiinflammatory response to infection
could be different from healthy children, similar to the
different levels of suppression caused by light exposure in
different stages of puberty.
On the other hand, it is known that COVID-19 usually
has a mild course in pediatric patients [14–15]. As such,
approximately 90% of pediatric patients who do not have
comorbidities usually exhibit mild or moderate symptoms
with relatively lower morbidity rates. Detection of high
serum melatonin levels in pediatric COVID-19 patients
has strengthened the theory that melatonin may have
protective effects against the progression of COVID-19.
Since there were no severe COVID-19 cases in our study,
serum melatonin levels could not be compared between
mild or moderate cases and severe cases.
Lifestyle changes due to the COVID-19 pandemic
significantly increased the risk of sleep disorders both in
patients and healthy population [16–17]. Some studies
investigated the sleep disorders in patients who stayed in
self-isolation or who were hospitalized for long periods
or those who had a history of long-term admission to the
intensive care unit. In one of these studies, the frequency
of insomnia was 17.4% in Italian patients quarantined
for 14 days [16]. Another study from Taiwan investigated
sleep disorders in social media users and reported
that the rate of sleep disturbances was 55.8% in this
patient population [17]. Also, a French study presented
complicated sleep disturbance cases in the young adult
population during the pandemic period [18].
It is widely accepted that melatonin prevents sleep
deprivation, reduces delirium risk, and shortens the
length of stay in patients staying at intensive care units
[19]. Our literature did not reveal any studies investigating
the impact of COVID-19 on sleep parameters in the
pediatric patient population. One of our aims was to
investigate the changes in children’s sleep patterns with
COVID-19 and compare these changes with the changes
detected in a group of children who had nonspecific
upper respiratory tract infections by questioning the
primary caregivers of the participants. The two groups
showed similar results in both evaluations regarding
the present time and 6 months before symptom onset.
Similarly, no difference was found by comparing the
SDSC scores concerning present time and six months
before symptom onset. These results demonstrated that
COVID-19 did not cause any significant changes in the
sleep patterns of children.
It was reported that melatonin decreased sleep onset
latency and prolonged total sleep time [20]. Although
the serum melatonin levels of all study participants
were higher than the reference values in our study, no

difference was detected in sleep parameters related to
initiating and maintaining sleep. We aimed to take serum
samples under similar temporal and environmental
conditions considering that a difference of even 1 h can
result in a significant difference in melatonin levels. It
is also known that changes in sleep timing or exposure
to light in the evening can result in different melatonin
onset times, leading to different melatonin levels in the
following morning [21]. Therefore, although we aimed to
obtain standardized conditions, the wide range observed
in the serum melatonin levels might have been caused by
the inevitable differences in the conditions.
Our study has some limitations which need to be
considered while evaluating its findings. First, the SDSC
questionnaires were performed by phone. Although the
optimal method of performing a questionnaire is inperson interviews, we had to conduct them on the phone
due to contact isolation. Second, the primary caregiver
was expected to give sleep-related information regarding
the present time and 6 months before symptom onset.
The reliability of the latter can be considered doubtful.
Third, since there were no severe COVID-19 cases in our
cohort, we could not compare the serum melatonin levels
of mild or moderate COVID-19 cases with those of severe
cases. This limitation is significant because melatonin is
used for adjuvant treatment of some patients with severe
COVID-19 who are followed in intensive care units [1].
Our study showed that COVID-19 did not cause
any changes in sleep parameters of children. Although
we detected that serum melatonin levels of all patients
participating in our study were higher than the ageadjusted reference values, they were higher in the nonCOVID-19 patient group than the patients diagnosed
with COVID-19. This finding does not support our
hypothesis; however, serum melatonin levels higher than
the reference range in pediatric patients with COVID-19
can be considered as a sign of melatonin’s protective
effect in these patients. Nevertheless, our results need to
be confirmed by further prospective studies conducted
with more extensive patient series.
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Appendix. SDSC scores of the participants at 6 months prior to onset and the last week of infection.
COVID-19-positive COVID-19-negative
P-value
(n: 65)
(n: 20)
SDSC where the sleep features of the last week of infection were evaluated 27 (24–43)

27 (24–42)

0.979

Disorders of initiating and maintaining sleep

9 (7–16)

8 (7–15)

0.992

Sleep-wake transition disorders

4 (3–8)

4 (4–8)

0.829

Sleep breathing disorders

3 (3–9)

3 (3–7)

0.350

Sleep hyperhidrosis

2 (2–7)

2 (1–4)

0.583

Disorders of excessive somnolence

5 (4–8)

5 (5–13)

0.956

Disorders of arousal

3 (3–7)

3 (3–7)

0.451

SDSC where the sleep features at 6 months prior to onset were evaluated

27 (24–46)

29 (24–52)

0.476

Disorders of initiating and maintaining sleep

9 (7–17)

10.5 (7–17)

0.109

Sleep-wake transition disorders

4 (3–9)

4 (4–8)

0.618

Sleep breathing disorders

3 (3–9)

3 (3–7)

0.654

Sleep hyperhidrosis

2 (2–7)

2 (1–5)

0.685

Disorders of excessive somnolence

5 (4–13)

5 (5–13)

0.405

Disorders of arousal

3 (3–8)

3 (3–7)

0.698
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